Study of Lyme disease during anti-CD20 treatment in France
Part of Infections clinical trials.
This study looks at people who got a serious form of Lyme disease while being treated with a type of biologic drug called an anti-CD20 (such as rituximab). The goal is to learn more about these cases and improve care. You may join if you had Lyme disease confirmed by a DNA test within two years of taking this medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child or adult (any age).
- You had a serious type of Lyme disease (called disseminated borreliosis) that was confirmed by a DNA test.
- You got this Lyme infection while you were taking an anti-CD20 drug (like rituximab or similar).
- The anti-CD20 treatment happened between January 1, 2010 and July 30, 2025.
- You agree to take part in the study (no one will be included who refuses).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new blood test to help diagnose Lyme disease (borrelia infection) in children. If you are at the emergency room with symptoms that might be Lyme disease and you have a healthy immune system, you might be able to join.
This study looks at how your immune system responds to the bacteria that causes Lyme disease. It may help doctors better understand the disease and improve treatment. The trial includes people with a specific form of Lyme called acrodermatitis chronica atrophicans (a skin condition) and healthy volunteers.
This study looks at people who have had Lyme disease more than once after traveling abroad. It aims to understand the patterns of the infection and why it comes back.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This study evaluates and treats people who currently have active Lyme disease, as defined by CDC criteria. It aims to provide expert care and follow-up while studying the disease.
This study looks at whether certain antibodies (called anti-phospholipid antibodies) are present in people with Lyme disease. It may help doctors understand how the infection affects the body's immune system.
Hear when a new Borrelia Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.